Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study

Abstract Background IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available. Objectives To evaluate safet...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Vaccine 2016-08, Vol.34 (38), p.4579-4585
Hauptverfasser: Cramer, Jakob P, Dubischar, Katrin, Eder, Susanne, Burchard, Gerd D, Jelinek, Tomas, Jilma, Bernd, Kollaritsch, Herwig, Reisinger, Emil, Westritschnig, Kerstin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4585
container_issue 38
container_start_page 4579
container_title Vaccine
container_volume 34
creator Cramer, Jakob P
Dubischar, Katrin
Eder, Susanne
Burchard, Gerd D
Jelinek, Tomas
Jilma, Bernd
Kollaritsch, Herwig
Reisinger, Emil
Westritschnig, Kerstin
description Abstract Background IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available. Objectives To evaluate safety and immunogenicity of IXIARO in elderly subjects. Methods Open-label, single arm, multi-centered study. Two-hundred subjects with good general health, including adequately controlled chronic conditions, received two doses of IXIARO®, 28 days apart. Protective levels of antibodies were tested 42 days after the second dose. Systemic and local adverse events (AEs) were solicited for 7 days after each dose, unsolicited AEs were collected up to day 70 and in a phone call at month 7. Summary of results Subjects were aged 64–83 years (median 69.0 years). Nineteen percent of subjects had serious or medically attended AEs up to Day 70 (primary endpoint), none of them causally linked to IXIARO. Solicited local AEs were reported by 33.5% (most common: local tenderness) and solicited systemic AEs by 27% (most common: headache) of subjects. The seroprotection rate was 65% with a geometric mean titre (GMT) of 37. Subjects with tick borne encephalitis (TBE) vaccinations in the past 5 years ( N = 29) had a SCR of 90% and GMT of 65. Conclusions IXIARO is generally well tolerated in the elderly, and the safety profile is largely comparable with younger adults. SCR and GMT are lower compared to younger adults, but SCR is in the range reported in elderly for other vaccines e.g. against TBE, hepatitis-A virus (HAV)/hepatitis-B virus (HBV), influenza. The differences in SCR and GMT from younger to elderly adults were in the range of other vaccines. Duration of protection is uncertain in older persons, therefore a booster dose (third dose) should be considered before any further exposure to JE virus.
doi_str_mv 10.1016/j.vaccine.2016.07.029
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1814143942</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0264410X16306120</els_id><sourcerecordid>4316560381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-9efb1d9bc9e8aa930bcb6dd21a4061278cbe2af2571022bf4264b1bb594eb5dc3</originalsourceid><addsrcrecordid>eNqFksuKFDEUhgtRnHb0EZSAGxddZZJK3VyMDIOXloEGLzC7kMspJ2Uq1Saphn4ZH8GH8MlM0a3CbFwlge_8Oef_T5Y9JbggmNQvh2IvlDIOCpqeBW4KTLt72Yq0TZnTirT3sxWmNcsZwTdn2aMQBoxxVZLuYXZGG1bjqsKr7MdmHGc3fQVnlIkHJJxGQfSQrlOP4i0g44SKZi8iaPRB7ISDAAicgt2tsCaagE6NoM3N5vLj9tfPVILAavD2gMIsB1AxvELbHbjcCgl2jWanJhf9ZC3oNRpnG02uwEXwa5Rk0wcMhTjrw-PsQS9sgCen8zz78vbN56v3-fX23ebq8jpXjLUx76CXRHdSddAK0ZVYKllrTYlguCa0aZUEKnpaNQRTKnuWjJFEyqpjICutyvPsxVF356fvM4TIRxMUWJvGnebASUsYYWXHaEKf30GHafYudZeoBtdl01GSqOpIKT-F4KHnO29G4Q-cYL4EyAd-8o0vAXLc8BRgqnt2Up_lCPpv1Z_EEvD6CECyY2_A86DMEoc2PhnN9WT--8XFHQVlTYpf2G9wgPBvGh4ox_zTskXLEpG6XMzE5W9-v8bI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1870637921</pqid></control><display><type>article</type><title>Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cramer, Jakob P ; Dubischar, Katrin ; Eder, Susanne ; Burchard, Gerd D ; Jelinek, Tomas ; Jilma, Bernd ; Kollaritsch, Herwig ; Reisinger, Emil ; Westritschnig, Kerstin</creator><creatorcontrib>Cramer, Jakob P ; Dubischar, Katrin ; Eder, Susanne ; Burchard, Gerd D ; Jelinek, Tomas ; Jilma, Bernd ; Kollaritsch, Herwig ; Reisinger, Emil ; Westritschnig, Kerstin</creatorcontrib><description>Abstract Background IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available. Objectives To evaluate safety and immunogenicity of IXIARO in elderly subjects. Methods Open-label, single arm, multi-centered study. Two-hundred subjects with good general health, including adequately controlled chronic conditions, received two doses of IXIARO®, 28 days apart. Protective levels of antibodies were tested 42 days after the second dose. Systemic and local adverse events (AEs) were solicited for 7 days after each dose, unsolicited AEs were collected up to day 70 and in a phone call at month 7. Summary of results Subjects were aged 64–83 years (median 69.0 years). Nineteen percent of subjects had serious or medically attended AEs up to Day 70 (primary endpoint), none of them causally linked to IXIARO. Solicited local AEs were reported by 33.5% (most common: local tenderness) and solicited systemic AEs by 27% (most common: headache) of subjects. The seroprotection rate was 65% with a geometric mean titre (GMT) of 37. Subjects with tick borne encephalitis (TBE) vaccinations in the past 5 years ( N = 29) had a SCR of 90% and GMT of 65. Conclusions IXIARO is generally well tolerated in the elderly, and the safety profile is largely comparable with younger adults. SCR and GMT are lower compared to younger adults, but SCR is in the range reported in elderly for other vaccines e.g. against TBE, hepatitis-A virus (HAV)/hepatitis-B virus (HBV), influenza. The differences in SCR and GMT from younger to elderly adults were in the range of other vaccines. Duration of protection is uncertain in older persons, therefore a booster dose (third dose) should be considered before any further exposure to JE virus.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2016.07.029</identifier><identifier>PMID: 27460550</identifier><language>eng</language><publisher>Netherlands: Elsevier Ltd</publisher><subject>Age ; Aged ; Aged, 80 and over ; Allergy and Immunology ; Antibodies, Viral - blood ; Austria ; Clinical trials ; Disease ; Elderly ; Encephalitis ; Encephalitis, Japanese - prevention &amp; control ; Female ; Fever ; Germany ; Hepatitis ; Humans ; Immunization, Secondary ; Immunogenicity ; Immunogenicity, Vaccine ; Influenza ; Japanese encephalitis ; Japanese Encephalitis Vaccines - adverse effects ; Japanese Encephalitis Vaccines - immunology ; Japanese Encephalitis Vaccines - therapeutic use ; Male ; Older people ; Population ; Prospective Studies ; Public health ; Safety ; Seroconversion ; Tropical diseases ; Vaccine ; Vaccines ; Vector-borne diseases</subject><ispartof>Vaccine, 2016-08, Vol.34 (38), p.4579-4585</ispartof><rights>2016</rights><rights>Copyright © 2016. Published by Elsevier Ltd.</rights><rights>Copyright Elsevier Limited Aug 31, 2016</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-9efb1d9bc9e8aa930bcb6dd21a4061278cbe2af2571022bf4264b1bb594eb5dc3</citedby><cites>FETCH-LOGICAL-c448t-9efb1d9bc9e8aa930bcb6dd21a4061278cbe2af2571022bf4264b1bb594eb5dc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0264410X16306120$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27460550$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cramer, Jakob P</creatorcontrib><creatorcontrib>Dubischar, Katrin</creatorcontrib><creatorcontrib>Eder, Susanne</creatorcontrib><creatorcontrib>Burchard, Gerd D</creatorcontrib><creatorcontrib>Jelinek, Tomas</creatorcontrib><creatorcontrib>Jilma, Bernd</creatorcontrib><creatorcontrib>Kollaritsch, Herwig</creatorcontrib><creatorcontrib>Reisinger, Emil</creatorcontrib><creatorcontrib>Westritschnig, Kerstin</creatorcontrib><title>Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study</title><title>Vaccine</title><addtitle>Vaccine</addtitle><description>Abstract Background IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available. Objectives To evaluate safety and immunogenicity of IXIARO in elderly subjects. Methods Open-label, single arm, multi-centered study. Two-hundred subjects with good general health, including adequately controlled chronic conditions, received two doses of IXIARO®, 28 days apart. Protective levels of antibodies were tested 42 days after the second dose. Systemic and local adverse events (AEs) were solicited for 7 days after each dose, unsolicited AEs were collected up to day 70 and in a phone call at month 7. Summary of results Subjects were aged 64–83 years (median 69.0 years). Nineteen percent of subjects had serious or medically attended AEs up to Day 70 (primary endpoint), none of them causally linked to IXIARO. Solicited local AEs were reported by 33.5% (most common: local tenderness) and solicited systemic AEs by 27% (most common: headache) of subjects. The seroprotection rate was 65% with a geometric mean titre (GMT) of 37. Subjects with tick borne encephalitis (TBE) vaccinations in the past 5 years ( N = 29) had a SCR of 90% and GMT of 65. Conclusions IXIARO is generally well tolerated in the elderly, and the safety profile is largely comparable with younger adults. SCR and GMT are lower compared to younger adults, but SCR is in the range reported in elderly for other vaccines e.g. against TBE, hepatitis-A virus (HAV)/hepatitis-B virus (HBV), influenza. The differences in SCR and GMT from younger to elderly adults were in the range of other vaccines. Duration of protection is uncertain in older persons, therefore a booster dose (third dose) should be considered before any further exposure to JE virus.</description><subject>Age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Allergy and Immunology</subject><subject>Antibodies, Viral - blood</subject><subject>Austria</subject><subject>Clinical trials</subject><subject>Disease</subject><subject>Elderly</subject><subject>Encephalitis</subject><subject>Encephalitis, Japanese - prevention &amp; control</subject><subject>Female</subject><subject>Fever</subject><subject>Germany</subject><subject>Hepatitis</subject><subject>Humans</subject><subject>Immunization, Secondary</subject><subject>Immunogenicity</subject><subject>Immunogenicity, Vaccine</subject><subject>Influenza</subject><subject>Japanese encephalitis</subject><subject>Japanese Encephalitis Vaccines - adverse effects</subject><subject>Japanese Encephalitis Vaccines - immunology</subject><subject>Japanese Encephalitis Vaccines - therapeutic use</subject><subject>Male</subject><subject>Older people</subject><subject>Population</subject><subject>Prospective Studies</subject><subject>Public health</subject><subject>Safety</subject><subject>Seroconversion</subject><subject>Tropical diseases</subject><subject>Vaccine</subject><subject>Vaccines</subject><subject>Vector-borne diseases</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFksuKFDEUhgtRnHb0EZSAGxddZZJK3VyMDIOXloEGLzC7kMspJ2Uq1Saphn4ZH8GH8MlM0a3CbFwlge_8Oef_T5Y9JbggmNQvh2IvlDIOCpqeBW4KTLt72Yq0TZnTirT3sxWmNcsZwTdn2aMQBoxxVZLuYXZGG1bjqsKr7MdmHGc3fQVnlIkHJJxGQfSQrlOP4i0g44SKZi8iaPRB7ISDAAicgt2tsCaagE6NoM3N5vLj9tfPVILAavD2gMIsB1AxvELbHbjcCgl2jWanJhf9ZC3oNRpnG02uwEXwa5Rk0wcMhTjrw-PsQS9sgCen8zz78vbN56v3-fX23ebq8jpXjLUx76CXRHdSddAK0ZVYKllrTYlguCa0aZUEKnpaNQRTKnuWjJFEyqpjICutyvPsxVF356fvM4TIRxMUWJvGnebASUsYYWXHaEKf30GHafYudZeoBtdl01GSqOpIKT-F4KHnO29G4Q-cYL4EyAd-8o0vAXLc8BRgqnt2Up_lCPpv1Z_EEvD6CECyY2_A86DMEoc2PhnN9WT--8XFHQVlTYpf2G9wgPBvGh4ox_zTskXLEpG6XMzE5W9-v8bI</recordid><startdate>20160831</startdate><enddate>20160831</enddate><creator>Cramer, Jakob P</creator><creator>Dubischar, Katrin</creator><creator>Eder, Susanne</creator><creator>Burchard, Gerd D</creator><creator>Jelinek, Tomas</creator><creator>Jilma, Bernd</creator><creator>Kollaritsch, Herwig</creator><creator>Reisinger, Emil</creator><creator>Westritschnig, Kerstin</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20160831</creationdate><title>Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study</title><author>Cramer, Jakob P ; Dubischar, Katrin ; Eder, Susanne ; Burchard, Gerd D ; Jelinek, Tomas ; Jilma, Bernd ; Kollaritsch, Herwig ; Reisinger, Emil ; Westritschnig, Kerstin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-9efb1d9bc9e8aa930bcb6dd21a4061278cbe2af2571022bf4264b1bb594eb5dc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Allergy and Immunology</topic><topic>Antibodies, Viral - blood</topic><topic>Austria</topic><topic>Clinical trials</topic><topic>Disease</topic><topic>Elderly</topic><topic>Encephalitis</topic><topic>Encephalitis, Japanese - prevention &amp; control</topic><topic>Female</topic><topic>Fever</topic><topic>Germany</topic><topic>Hepatitis</topic><topic>Humans</topic><topic>Immunization, Secondary</topic><topic>Immunogenicity</topic><topic>Immunogenicity, Vaccine</topic><topic>Influenza</topic><topic>Japanese encephalitis</topic><topic>Japanese Encephalitis Vaccines - adverse effects</topic><topic>Japanese Encephalitis Vaccines - immunology</topic><topic>Japanese Encephalitis Vaccines - therapeutic use</topic><topic>Male</topic><topic>Older people</topic><topic>Population</topic><topic>Prospective Studies</topic><topic>Public health</topic><topic>Safety</topic><topic>Seroconversion</topic><topic>Tropical diseases</topic><topic>Vaccine</topic><topic>Vaccines</topic><topic>Vector-borne diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cramer, Jakob P</creatorcontrib><creatorcontrib>Dubischar, Katrin</creatorcontrib><creatorcontrib>Eder, Susanne</creatorcontrib><creatorcontrib>Burchard, Gerd D</creatorcontrib><creatorcontrib>Jelinek, Tomas</creatorcontrib><creatorcontrib>Jilma, Bernd</creatorcontrib><creatorcontrib>Kollaritsch, Herwig</creatorcontrib><creatorcontrib>Reisinger, Emil</creatorcontrib><creatorcontrib>Westritschnig, Kerstin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Proquest Nursing &amp; Allied Health Source</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cramer, Jakob P</au><au>Dubischar, Katrin</au><au>Eder, Susanne</au><au>Burchard, Gerd D</au><au>Jelinek, Tomas</au><au>Jilma, Bernd</au><au>Kollaritsch, Herwig</au><au>Reisinger, Emil</au><au>Westritschnig, Kerstin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study</atitle><jtitle>Vaccine</jtitle><addtitle>Vaccine</addtitle><date>2016-08-31</date><risdate>2016</risdate><volume>34</volume><issue>38</issue><spage>4579</spage><epage>4585</epage><pages>4579-4585</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>Abstract Background IXIARO® is a Vero cell-derived, inactivated Japanese encephalitis (JE) vaccine licensed mainly in western countries for children and adults traveling to JE endemic areas. Limited immunogenicity and safety data in elderly travelers have been available. Objectives To evaluate safety and immunogenicity of IXIARO in elderly subjects. Methods Open-label, single arm, multi-centered study. Two-hundred subjects with good general health, including adequately controlled chronic conditions, received two doses of IXIARO®, 28 days apart. Protective levels of antibodies were tested 42 days after the second dose. Systemic and local adverse events (AEs) were solicited for 7 days after each dose, unsolicited AEs were collected up to day 70 and in a phone call at month 7. Summary of results Subjects were aged 64–83 years (median 69.0 years). Nineteen percent of subjects had serious or medically attended AEs up to Day 70 (primary endpoint), none of them causally linked to IXIARO. Solicited local AEs were reported by 33.5% (most common: local tenderness) and solicited systemic AEs by 27% (most common: headache) of subjects. The seroprotection rate was 65% with a geometric mean titre (GMT) of 37. Subjects with tick borne encephalitis (TBE) vaccinations in the past 5 years ( N = 29) had a SCR of 90% and GMT of 65. Conclusions IXIARO is generally well tolerated in the elderly, and the safety profile is largely comparable with younger adults. SCR and GMT are lower compared to younger adults, but SCR is in the range reported in elderly for other vaccines e.g. against TBE, hepatitis-A virus (HAV)/hepatitis-B virus (HBV), influenza. The differences in SCR and GMT from younger to elderly adults were in the range of other vaccines. Duration of protection is uncertain in older persons, therefore a booster dose (third dose) should be considered before any further exposure to JE virus.</abstract><cop>Netherlands</cop><pub>Elsevier Ltd</pub><pmid>27460550</pmid><doi>10.1016/j.vaccine.2016.07.029</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0264-410X
ispartof Vaccine, 2016-08, Vol.34 (38), p.4579-4585
issn 0264-410X
1873-2518
language eng
recordid cdi_proquest_miscellaneous_1814143942
source MEDLINE; Elsevier ScienceDirect Journals
subjects Age
Aged
Aged, 80 and over
Allergy and Immunology
Antibodies, Viral - blood
Austria
Clinical trials
Disease
Elderly
Encephalitis
Encephalitis, Japanese - prevention & control
Female
Fever
Germany
Hepatitis
Humans
Immunization, Secondary
Immunogenicity
Immunogenicity, Vaccine
Influenza
Japanese encephalitis
Japanese Encephalitis Vaccines - adverse effects
Japanese Encephalitis Vaccines - immunology
Japanese Encephalitis Vaccines - therapeutic use
Male
Older people
Population
Prospective Studies
Public health
Safety
Seroconversion
Tropical diseases
Vaccine
Vaccines
Vector-borne diseases
title Immunogenicity and safety of the inactivated Japanese encephalitis vaccine IXIARO® in elderly subjects: Open-label, uncontrolled, multi-center, phase 4 study
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T22%3A50%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunogenicity%20and%20safety%20of%20the%20inactivated%20Japanese%20encephalitis%20vaccine%20IXIARO%C2%AE%20in%20elderly%20subjects:%20Open-label,%20uncontrolled,%20multi-center,%20phase%204%20study&rft.jtitle=Vaccine&rft.au=Cramer,%20Jakob%20P&rft.date=2016-08-31&rft.volume=34&rft.issue=38&rft.spage=4579&rft.epage=4585&rft.pages=4579-4585&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2016.07.029&rft_dat=%3Cproquest_cross%3E4316560381%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1870637921&rft_id=info:pmid/27460550&rft_els_id=S0264410X16306120&rfr_iscdi=true